Unicycive Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 4300 EL CAMINO REAL, SUITE 210, LOS ALTOS, CA, 94022
Mailing Address 4300 EL CAMINO REAL, SUITE 210, LOS ALTOS, CA, 94022
Phone 650-384-0642
Fiscal Year End 1231
EIN 813638692
Financial Overview
FY2025
$30.20M
Stockholders' Equity
$-1.67
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 10, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 23, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| 8-K Current report of material events | November 14, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
Annual Reports
10-K March 30, 2026
- Lead drug OLC has a critical FDA target decision date of June 29, 2026.
- Resubmission of OLC application follows successful resolution of manufacturing quality control issues.
Related Companies
Companies in the same industry (SIC: 2834)
NERVGEN PHARMA CORP.
NGEN Pharmaceutical Preparations
Connect Biopharma Holdings Ltd
CNTB Pharmaceutical Preparations
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
LIXT Pharmaceutical Preparations
TuHURA Biosciences, Inc./NV
HURA Pharmaceutical Preparations
Canton Strategic Holdings, Inc.
CNTN Pharmaceutical Preparations
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.